EC, EMEA and FDA confirm their commitment to cooperation on advancing medicines

The European Commission, the European Medicines Agency (EMEA) and the US Food and Drug Administration have affirmed their commitment to regulatory cooperation and to intensifying their interactions in several new areas.

Meeting in the UK for the annual review of cooperative activities undertaken under the scope of their confidentiality arrangements, the European Union and US authorities agreed to expand collaboration in the areas of advanced-therapy medicines and nanotechnology-derived medicinal products, as well as on the exchange of pharmacovigilance information.